



## First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function



Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0054.R2
Wiley - Manuscript type:	Mutation in Brief
Date Submitted by the Author:	02-Apr-2010
Complete List of Authors:	<p>Piters, Elke; University of Antwerp, Department of Medical Genetics  Culha, Cavit; Ankara Training and Research Hospital, Department of Endocrinology and Metabolism  Moester, Martiene; Leiden University Medical Centre, Department of Endocrinology and Metabolic Diseases  Van Bezooijen, Rutger; Leiden University Medical Centre, Department of Endocrinology and Metabolic Diseases  Adriaensen, Dirk; University of Antwerp, Laboratory of Cell Biology and Histology  Mueller, Thomas; University of Würzburg, Department of Molecular Plant Physiology and Biophysics  Weidauer, Stella; University of Würzburg, Department of Molecular Plant Physiology and Biophysics  Jennes, Karen; University of Antwerp, Department of Medical Genetics  de Freitas, Fenna; University of Antwerp, Department of Medical Genetics  Timmermans, Jean-Pierre; University of Antwerp, Laboratory of Cell Biology and Histology  Van Hul, Wim; University of Antwerp, Department of Medical Genetics  Papapoulos, Socrates; Leiden University Medical Centre, Department of Endocrinology and Metabolic Diseases</p>
Key Words:	sost, sclerostin, Wnt signaling, sclerosteosis



# First Missense Mutation in the *SOST* Gene Causing Sclerosteosis by Loss of Sclerostin Function



Elke Piters<sup>1</sup>, Cavit Culha<sup>2</sup>, Martiene Moester<sup>3</sup>, Rutger Van Bezooijen<sup>3</sup>, Dirk Adriaensen<sup>4</sup>, Thomas Mueller<sup>5</sup>, Stella Weidauer<sup>5</sup>, Karen Jennes<sup>1</sup>, Fenna de Freitas<sup>1</sup>, Jean-Pierre Timmermans<sup>4</sup>, Wim Van Hul<sup>1</sup>, and Socrates Papapoulos<sup>3</sup>

<sup>1</sup>Department of Medical Genetics, University of Antwerp, Belgium, <sup>2</sup>Department of Endocrinology and Metabolism, Ankara Training and Research Hospital, Turkey, <sup>3</sup>Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, The Netherlands, <sup>4</sup>Laboratory of Cell Biology and Histology, University of Antwerp, Belgium, <sup>5</sup>Department of Molecular Plant Physiology and Biophysics, University of Würzburg, Germany

\*Correspondence to Wim Van Hul, Department of Medical Genetics, University of Antwerp, Prins Boudewijnlaan 43, 2650 Edegem, Belgium; Tel +32 (0)3 275 9761; Fax +32 (0)3 275 9722; E-mail: wim.vanhul@ua.ac.be.

Communicated by Iain McIntosh

**ABSTRACT:** Sclerosteosis is a rare bone dysplasia characterized by greatly increased bone mass, especially of the long bones and the skull. Patients are tall, show facial asymmetry and often have syndactyly. Clinical complications are due to entrapment of cranial nerves. The disease is thought to be due to loss-of-function mutations in the *SOST* gene. The *SOST* gene product, sclerostin, is secreted by osteocytes and transported to the bone surface where it inhibits osteoblastic bone formation by antagonizing Wnt signaling. In a small Turkish family with sclerosteosis, we identified a missense mutation (c.499T>C; p.Cys167Arg) in exon 2 of the *SOST* gene. This type of mutation has not been previously reported and using different functional approaches, we show that it has a devastating effect on the biological function of sclerostin. The affected cysteine is the last cysteine residue of the cystine-knot motif and loss of this residue leads to retention of the mutant protein in the ER, possibly as a consequence of impaired folding. Together with a significant reduced ability to bind to LRP5 and inhibit Wnt signaling, the p.Cys167Arg mutation leads to a complete loss of function of sclerostin and thus to the characteristic sclerosteosis phenotype. ©2010 Wiley-Liss, Inc.

**KEY WORDS:** *SOST*, sclerostin, Wnt signaling, sclerosteosis

## INTRODUCTION

Bone mineral density (BMD) in humans is a quantitative trait determined to a great extent by genetic factors (Gueguen, et al., 1995; Krall and Dawson-Hughes, 1993). The involvement of genes has been clearly demonstrated in patients with sclerosing bone dysplasias, a heterogeneous group of 40 different monogenetic diseases associated with increased BMD. One subgroup comprises the craniotubular hyperostoses, mainly

Received 3 February 2010; accepted revised manuscript 12 April 2010.

© 2010 WILEY-LISS, INC.

## 2 Piters et al.

1  
2  
3 characterized by increased cortical thickness of the long bones and the skull (Balemans, et al., 2005b; Johnson, et  
4 al., 2004). Sclerosteosis (SCL; MIM# 269500) and Van Buchem disease (VBD; MIM# 239100) are two closely  
5 related, rare craniotubular hyperostoses with an autosomal recessive mode of inheritance.

6  
7 Patients with SCL show progressive bone overgrowth and thickening, especially of the skull, the mandible and  
8 the tubular bones. Patients are tall and have facial distortion due to enlargement of the mandible and forehead.  
9 Entrapment of cranial nerves often results in facial nerve palsy, hearing loss, and loss of smell. Calvarial  
10 overgrowth leads to elevated intracranial pressure causing headache and occasionally sudden death. The majority  
11 of patients with SCL have some degree of hand malformations, mainly syndactyly. These features are not present  
12 in patients with VBD and together with tall stature, may allow the clinical differentiation of the two conditions  
13 (Beighton, et al., 1984; Beighton, et al., 1977; Beighton, et al., 1976; Hamersma, et al., 2003). Sclerosteosis has a  
14 high prevalence in the Afrikaner population in South-Africa. In addition, it has been reported in isolated  
15 individuals or families from Spain, Brazil, the USA, Germany, Japan and Senegal (A Freire de Paes Alves, 1982;  
16 Bueno, et al., 1994; CH Kelley, 1946; NL Higinbotham, 1941; Pietruschka, 1958; Stein, et al., 1983; Sugiura and  
17 Yasuhara, 1975; Tacconi, et al., 1998). Apart from an isolated family in Scotland, patients with VBD are Dutch,  
18 originating from an isolated community in The Netherlands (Dixon, et al., 1982). Because the Africaner population  
19 is of Dutch origin, it was assumed that SCL and VBD were caused by the same genetic defect. The mapping of  
20 SCL to locus 17q12-21, the region that was also shown to contain the gene responsible for VBD, further supported  
21 this hypothesis (Balemans, et al., 1999; Van Hul, et al., 1998). However, genetic analysis revealed that the two  
22 conditions have a different genetic defect. Through positional cloning, Balemans *et al.* identified two homozygous  
23 nonsense mutations (c.372G>A (p.Trp124X); c.376C>T (p.Arg126X)) in a Brazilian and an American SCL  
24 family, respectively, and a splice site mutation (c.220+3A>T) in a Senegalese patient with SCL in the previously  
25 unknown *SOST* gene (MIM# 605740) (Balemans, et al., 2001). Simultaneously, Brunkow *et al.* identified a  
26 homozygous nonsense mutation (c.70C>T (p.Gln24X)) in affected individuals from South Africa. The nonsense  
27 mutations lead to premature termination of the protein, while the c.220+3A>T mutation was shown to alter  
28 splicing of the *SOST* gene (Brunkow, et al., 2001). In 2005, another splice-site mutation (c.220+1G>C) in the  
29 *SOST* gene was reported in two affected siblings of German origin, putatively disease-causing in the same way as  
30 the c.220+3A>T mutation (Balemans, et al., 2005a). In the Dutch patients diagnosed with VBD no *SOST* mutation  
31 was present, but a 52kb deletion downstream of the *SOST* gene was identified. This deleted region harbours an  
32 enhancer element that drives the expression of the *SOST* gene explaining the similarities between the two  
33 conditions (Balemans, et al., 2002; Staehling-Hampton, et al., 2002). All of the reported mutations in *SOST* as well  
34 as the deletion found in patients with VBD, result in the absence of expression of the *SOST* gene product sclerostin  
35 by osteocytes (van Bezooijen, et al., 2009; van Bezooijen, et al., 2004).

36  
37 In patients with SCL and VBD, the increase in BMD is due to increased bone formation (Hill, et al., 1986;  
38 Stein, et al., 1983; van Bezooijen, et al., 2004; van Bezooijen, et al., 2005). In addition, mouse models with  
39 deletion or overexpression of the *SOST* gene as well as *in vitro* studies of osteoblast proliferation and  
40 differentiation, matrix mineralization and apoptosis demonstrated that sclerostin has an inhibitory action on bone  
41 formation (Li, et al., 2008; Sutherland, et al., 2004; van Bezooijen, et al., 2004; van Bezooijen, et al., 2007;  
42 Winkler, et al., 2003). Although the precise molecular mechanism of action of sclerostin still needs to be  
43 elucidated, it has been shown that it antagonizes Wnt signaling and binds directly to the first two  $\beta$ -  
44 propellers of low density lipoprotein receptor related protein (LRP) 5, but does not compete with the binding of  
45 Wnt proteins to LRP5/6 receptors (Li, et al., 2005; Semenov, et al., 2005; van Bezooijen, et al., 2007). LRP5 is  
46 required for the transduction of Wnt signals and the first  $\beta$ -propeller domain of *LRP5* is known to harbour  
47 mutations causing a High Bone Mass (HBM) phenotype (Boyden, et al., 2002; Little, et al., 2002; Van  
48 Wesenbeeck, et al., 2003). This condition is also classified among the craniotubular hyperostoses and has an  
49 autosomal dominant mode of inheritance. For all these *LRP5* mutants, binding to sclerostin was found to be  
50 impaired (Balemans, et al., 2008; Ellies, et al., 2006; Semenov and He, 2006). Furthermore, just like in patients  
51 with VBD and SCL, the bone thickening is most obvious at the long bones and the mandible, favouring a shared  
52 pathogenesis with SCL and VBD (Piters, et al., 2008).

53  
54 In this paper, we describe the genetic analysis of a patient with SCL and her relatives resulting in the  
55 identification of the first missense mutation in the *SOST* gene. This mutation results in the exchange of a cysteine  
56 residue of the cystine-knot motif of sclerostin for a non-cysteine amino acid, a defect that leads to a complete loss  
57 of function of sclerostin due to retention of the mutated protein in the ER.  
58  
59  
60

## MATERIALS AND METHODS

### Mutation analysis

We analysed both exons of the SOST gene as well as exon 2, 3 and 4 of the LRP5 gene that comprise the first  $\beta$ -propeller domain of the LRP5 protein, in which all mutations causing craniotubular hyperostoses cluster. In a first step, amplification was performed by GoTaq DNA polymerase-mediated PCR (Promega Corporation, Madison, Wisconsin, USA). Primers used to generate fragments containing the exons and its exon-intron boundaries of the SOST gene were: forward primer (FW) 5'-AGAATTCTCTCCTCCACCC-3' and reverse primer (R) 5'-GTGCTACTGGAAGGTGGC-3' for exon 1 and FW 5'-CCCCTGCCCTGGGTTGC-3' and R 5'-CTTCCACCAGCTCTAGAGC-3' for exon 2. For LRP5, exon 2 was amplified using FW 5'-AACTTCCTGACAACGCCTTAGG-3' and R 5'-TGCCATTGAGGTTGGCCACC-3', exon 3 using FW 5'-CGATGGGTGAGATTTTAGGG-3' and R 5'-TGACGCTGTTCCAAGTTCTG-3', and exon 4 with FW 5'-GGGTCAGCAGCAATGACTGTCCGG-3' and R 5'-CCAGAGCATGGGCTTCTGCAGG-3'. Amplified fragments were verified by agarose gel electrophoresis and compared with the Generuler 100bp Plus DNA Ladder (Fermentas International Inc, Ontario, Canada). Primers and unincorporated deoxyribonucleotide triphosphates (dNTPs) were removed using exonuclease I (New England Biolabs, Inc, Ipswich, Massachusetts, USA) and calf intestine alkaline phosphatase (CIAP, Roche Applied Science, Hoffmann-La Roche AG, Basel, Switzerland). Sequencing was carried out directly on purified fragments with the ABI 310 Genetic Analyser (Applied Biosystems, Foster City, California, USA), using ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit, version 1.1 (Applied Biosystems, Foster City, California, USA). The BigDye XTerminator Purification Kit was used as purification method for DNA sequencing to remove unincorporated BigDye terminators.

### Expression constructs and in vitro mutagenesis

Alignment of the human sclerostin protein sequence (GenBank RefSeq NM\_025237.2) and its homologue in mouse (GenBank RefSeq NM\_024449.5) showed that c.493T>C (p.Cys165Arg) in mouse corresponds with c.499T>C (p.Cys167Arg) in human (nucleotide numbering refers to the cDNA RefSeq using the A of the ATG translation initiation codon as nucleotide +1). Using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California), we introduced this mutation in a pcDNA3.1 plasmid that produces a secreted form of the WT mouse sclerostin with a HA tag at the amino terminus (WT mSost-HA). This construct contains the following elements (5' to 3'): NheI site, IgG kappa light chain signal peptide sequence (QTHILLWVLLLWVQGSTD), HA tag sequence (YPYDVPDYA), two linker peptide residues (GA), EcoRI site, mSost lacking endogenous signal peptide, termination codon, and XhoI site. Following primers were used for in vitro mutagenesis: FW 5'-CCTCGTGCAAGCGCAAGCGCC-3' and R 5'-GGTGAGGCGCTTGCGCTTGCA-3'. The complete insert sequence was verified for the presence of the mutation and for the absence of PCR introduced errors, using FW 5'-ACCGAGTTGGTGTGCTCC-3' and R 5'-GCACAGCAGCTGCACCC-3' as primers for direct sequencing on plasmid DNA. Although the mouse Sost gene has high similarity with the human SOST gene in the affected region, a human SOST construct was also used and the p.Cys167Arg mutation was introduced by site-directed mutagenesis at Genscript, Piscataway, USA.

The expression construct mouse Wnt1-V5 was kindly provided by Bart Williams (Van Andel Research Institute, USA) and Mesdc2 by Bernadette Holdener (State University of New York, USA). Both untagged full-length human WT-LRP5 and truncated human WT-LRP5 lacking the transmembrane and cytoplasmic domains but with a c-myc epitope at the carboxy-terminus were obtained from Matthew Warman (Howard Hughes Medical Institute, Orthopaedic Research Laboratories, USA). Bert Vogelstein (The Johns Hopkins University School of Medicine, USA) provided the Topflash Wnt reporter construct (pGL3-OT) while the BAT-luc Wnt reporter construct was provided by Stefano Piccolo (University of Padua School of Medicine, Italy). The Renilla luciferase constructs pRL-TK and pRL-SV40 were purchased from Promega Corporation.

Red fluorescent protein (RFP) fusion proteins for WT and MT mouse Sost were generated using the above described WT and MT mSost-HA as a template. PCR amplification was performed to disrupt the termination codon and the complete region of interest was subcloned into a pTurboFP635-N vector (Evrogen JSC, Moscow,

#### 4 Piters et al.

Russia) to obtain WT and MT mSost-RFP, respectively. A vector encoding a termination codon in the mSost gene served as a negative control (ter-mSost-RFP).

#### Immunoblotting

The human embryonic kidney (HEK) cell line 293T obtained from Danny Huylebroeck (University of Leuven, Leuven, Belgium), was grown in DMEM (Gibco- Invitrogen Ltd, Paisley, UK) supplemented with FBS (10% v/v). Twenty-four h prior to transfection, HEK293T cells were plated at  $4 \times 10^5$  cells/well in 6-well plates. Cells were transiently transfected with either WT or MT mSost-HA or empty pcDNA3.1 vector (500ng/well) using FuGENE 6 (Roche Applied Science), according to the manufacturer's instructions. Twenty-four h after transfection, the culture medium was changed to 1ml serum-free DMEM and 48h after transfection, conditioned medium (CM) was collected and cells were lysed with 500 $\mu$ l radioimmune precipitation (RIPA) buffer per well (50mM Tris-HCl pH8.0; 150mM NaCl; 1% NP-40; 0.5% Na-deoxycholate; 0.1% SDS; complete protease inhibitor cocktail tablet (Roche Applied Science); benzonase endonuclease (Merck, Darmstadt, Germany)). Total protein in cell lysates was quantified using a bicinchoninic acid (BCA) assay (Pierce, Illinois, USA) with the purpose of loading equal protein amounts on SDS-PAGE. CM and cell lysates were diluted in 5x SDS-PAGE loading buffer and subjected to reducing SDS-PAGE. After transfer to a PVDF membrane, sclerostin-HA was detected using a rabbit polyclonal HA antibody (1:2000; BD Biosciences, San Diego, CA). Equal protein loading for lysate fractions was verified with a mouse  $\beta$ -actin antibody (1:5000; Sigma-Aldrich, St. Louis, MO). Secondary incubation was performed using a goat anti-rabbit IgG-HRP (1:10000; Biorad) and a sheep anti-mouse IgG-HRP (1:5000; Amersham Biosciences), respectively, for 2h at room temperature. Chemiluminescence detection was carried out using the Enhanced Chemiluminescence (ECL) Western Blotting Substrate (Pierce) according to the manufacturer's instructions.

#### Electrochemiluminescence assay by Meso-Scale Discovery (MSD)

HEK293T cells and Saos-2 human sarcoma cells (ATCC) were grown in DMEM supplemented with FBS (10% v/v). Twenty-four h prior to transfection, HEK293T and Saos-2 cells were plated at  $1.3 \times 10^5$  and  $4.5 \times 10^4$  cells/well in 24-well plates, respectively. Cells were transfected with WT and MT constructs of both mouse and human Sost/SOST or a control plasmid (empty pcDNA3.1). After 24h, medium was replaced and after further incubation for 24h, CM was collected and cells were lysed with 250 $\mu$ l MSD lysis buffer per well (20mM Tris-HCl pH7.5; 150mM NaCl; 1mM EDTA; 1mM EGTA; 1% Triton X-100; complete protease inhibitor cocktail tablet (Roche Applied Science); 10mM NaF) or total RNA was isolated for RT-PCR analysis. Sclerostin levels in CM and cell lysates were determined using the 96-well MULTI-ARRAY<sup>®</sup> human sclerostin assay of MSD according to the manufacturer's instructions and corrected for SOST mRNA expression as determined by RT-PCR analysis.

#### Co-localisation studies using confocal live cell imaging

HEK293T and Saos-2 cells were grown in DMEM supplemented with FBS (10% v/v). Twenty-four h prior to transfection, cells were plated at low-density ( $0.5 \times 10^5$  cells/well) in 24-well plates. Both cell types were transfected with WT or MT mSost-RFP plasmid DNA, or with the ter-mSost-RFP as an empty control (200ng). FuGENE 6 (Roche Applied Science) was used for transfection; FuGENE 6 reagent: DNA ratio was slightly higher for Saos-2 cells (4:1) than for HEK293T cells (6:1). Twenty-four h after transfection, medium was removed and cells were rinsed with 1x Hanks balanced salt solution (HBSS) (Gibco Invitrogen Ltd). In addition, staining with a green fluorescent tracer for live-cell ER labeling (ER-Tracker<sup>™</sup> Green (glibenclamide BODIPY<sup>®</sup> FL); Molecular Probes Invitrogen Ltd) was performed. Cells were incubated for 20min at 37°C after adding 1 $\mu$ M ER-Tracker<sup>™</sup> Green staining solution. Subsequently, the staining solution was replaced by probe-free medium and cells were imaged using an inverted microscope (Zeiss Axiovert 200; Carl Zeiss, Jena, Germany) attached to a microlens-enhanced dual spinning disk confocal system (UltraVIEW ERS, PerkinElmer, Seer Green, UK), equipped with a three-line (488, 568 and 647nm) argon-krypton laser. Red fluorescent fusion proteins (excitation maximum (ex max): 553nm; emission maximum (em max): 574nm) were excited by the 568nm line while the green ER stain (ex max: 504nm; em max: 511nm) was excited by the 488nm line. Fluorescence was recorded using 527/55nm and

615/70nm band pass filters, respectively. Multicolor high-resolution time-lapse images (4 images/s) of the living cells were captured over a time period of 5 min. Data were analyzed by Volocity 5 software (Improvision, PerkinElmer).

### Wnt activity reporter assays

Saos-2 cells were grown in DMEM supplemented with FBS (10% v/v). Twenty-four h prior to transfection, cells were plated at  $1.25 \times 10^5$  cells/well in 24-well plates and at  $6.75 \times 10^3$  cells/well in 96-well plates for stimulation with Wnt1-V5 and recombinant Wnt3A (rec Wnt3A), respectively. Cells were transfected using FuGENE 6 or FuGENE HD (Roche Applied Science), respectively, according to the manufacturer's instructions. For stimulation with Wnt1-V5 (100ng/well), cells were co-transfected with Mesdc2 (20ng/well), pGL3-OT reporter (100ng/well) and untagged full length WT-LRP5 (20ng/well) in the presence or absence of WT or MT mSost-HA (40ng/well). For stimulation with rec Wnt3A, cells were transfected with untagged full length WT-LRP5 (40ng/well) and BAT-luc (20ng/well) and stimulated with 30ng/ml rec Wnt3A, 24h after the transfection. When necessary, empty pcDNA3.1 vector was added to make the total DNA amount equal for all transfection experiments. The Renilla luciferase constructs pRL-TK and pRL-SV40 were co-transfected to correct for transfection efficiency of Wnt1-V5 and rec Wnt3A, respectively. Forty-eight h after transfection, cells were lysed using 100 $\mu$ l passive lysis buffer (Promega Corporation). Firefly and Renilla luciferase activity were measured using the dual-luciferase reporter assay system (Promega Corporation) according to manufacturers' instructions.

### Co-immunoprecipitation

Conditioned media and cell lysates containing WT or MT-sclerostin-HA were obtained as described above. In case of LRP5, HEK293T cells were co-transfected with truncated human WT-LRP5-myc (1 $\mu$ g) and, in equal amounts, Mesdc2. Proper expression of LRP5-myc protein in CM was evaluated by immunoblotting with c-myc antibodies (clone 9E10; Sigma-Aldrich; dilution 1:5000). Rabbit polyclonal HA antibody was used to verify the presence of WT and MT sclerostin-HA in CM or total cell lysates. Equal protein loading for lysate fractions was verified using  $\beta$ -actin antibodies. Based on these results, sclerostin-containing CM or total cell lysates were diluted more in the co-immunoprecipitation (co-IP) reactions than LRP5-containing CM. Co-IP between sclerostin and LRP5 was carried out by mixing CM containing truncated WT-LRP5-myc with CM containing WT-sclerostin-HA or cell lysates containing MT-sclerostin-HA, respectively. For the co-IP reactions, EZ-view™ Red Anti-HA affinity gel (Sigma-Aldrich) was pre-blocked for 1h with 3% BSA (Sigma-Aldrich) in 1x TBS buffer (pH7.8) at 4°C using a rotation shaker. Hundred  $\mu$ l of CM containing WT-sclerostin-HA or cell lysates containing MT-sclerostin-HA was mixed with equivalent amounts of secreted LRP5 (total CM volume of 250 $\mu$ l), together with 45 $\mu$ l of pre-blocked EZ-view™ Red Anti-HA affinity gel. The final volume was adjusted to 1ml with 1x TBS, and incubated for 4h at 4°C using a rotation shaker. To remove unbound proteins, the affinity gel was washed at 4°C in wash buffer (50mM Tris-HCl pH7.5; 150mM NaCl; 0.1% Triton-X100) for 5 min, and then pelleted. Protein complexes were eluted by resuspending the pellets in 1x PBS buffer containing 100 $\mu$ g/ml HA-peptide (Sigma-Aldrich). After 15 min incubation at room temperature, supernatants were collected and stored for SDS-PAGE. To serve as a positive control for binding to the affinity column, IP was also performed by adding a comparable volume of CM containing WT-sclerostin-HA, or cell lysates containing MT-sclerostin-HA to the preblocked EZ-view™ Red Anti-HA affinity gel. In the same way, a comparable volume of CM containing truncated WT-LRP5-myc not expressing the HA-tag, was used as a negative control for IP on an anti-HA affinity gel. Following transfer to PVDF, LRP5-myc and sclerostin-HA were incubated with anti-c-myc and anti-HA, respectively. Subsequently, LRP5-myc and  $\beta$ -actin proteins were incubated with secondary anti-mouse IgG-HRP for 2h at room temperature; sclerostin-HA with a secondary goat anti-rabbit IgG-HRP. Chemiluminescence detection was carried as described above.

### Statistical analysis

Data are expressed as mean values  $\pm$  SD. Comparisons between two or more measurements for a single experiment were performed using a Student's t-test and one-way ANOVA, respectively. For a set of experiments,

**6 Piters et al.**


1  
2  
3 general linear model (GLM) was used. Values of  $p < 0.05$  were considered significant. In case of post hoc multiple  
4 comparisons, Bonferroni was used. All statistical tests were provided by the SPSS 15.0 software package (SPSS  
5 Inc.).  
6  
7

**Modeling of MT sclerostin**

8  
9  
10 Modeling of the effect of the mutation was based on the NMR structure of mouse sclerostin (PDB entry 2KD3).  
11 The coordinates comprising the residues Asn59 to Arg167 of mouse sclerostin (corresponding to residues Asn61 to  
12 Arg169 of human sclerostin) were used for the analysis. After adapting the numbering to human sclerostin residue  
13 Cys167 was replaced by arginine using the protein modeling tools of the software package Quanta2006 (Accelrys  
14 Inc, San Diego). Due to the previous amino acid Cys167 being involved in a disulfide bond with residue Cys109  
15 and the resulting steric clash with the large side chain of the Arg167 introduced, the side chain was manually  
16 reoriented such that the side chain of Arg167 pointed towards the solvent requiring changes in the backbone  
17 conformation of the lower part of the flexible loop (starting from residue Gly110). The structure was subsequently  
18 refined by energy minimization runs; only geometrical energy terms without any electrostatic contribution were  
19 employed. Analysis of the resulting structure of MT sclerostin showed comparable statistics for backbone torsion  
20 angle distribution and van der Waals contacts. To test whether the replacement of Cys167 into Arg167 influences  
21 the flexibility of the loop, which has been proposed to contain the binding epitope of sclerostin for LRP5,  
22 molecular dynamics (MD) simulation runs were performed with or without NMR distance restraints derived for  
23 WT mouse sclerostin. All dynamics simulations were done using the software package Quanta2006 and the force  
24 field CHARMM22 without electrostatic energy terms (Accelrys Inc, San Diego), the non-bonded cut-off for van  
25 der Waals interactions was set to 10.5Å, the temperature of the bath was kept at 300K to allow for sufficient  
26 mobility of the atoms.  
27  
28

**RESULTS****Clinical description**

29  
30  
31  
32  
33 A 28-year old Turkish woman from a consanguineous marriage was recognized with clinical features  
34 suggestive of SCL (Figure 1A) and HBM during investigation of a multinodular goitre. She suffered from  
35 recurrent facial nerve palsies at the ages of 9, 14 and 15 years, complained of severe headaches, and had bilateral  
36 mixed-type hearing loss and right visual loss. Her height was 190cm, weight 76kg and head circumference  
37 66.5cm. The skull and jaw were enlarged, and she had proptosis and high arched palate. No syndactyly or other  
38 hand malformations were observed. Skull radiographs showed thickening of the calvarium (Figure 1B-C), an  
39 enlarged mandible and a highly increased BMD (T-score: spine +10.6, femoral neck +9.6). Endocrinological  
40 investigations revealed no abnormalities except for thyroid function compatible with subclinical hyperthyroidism.  
41 Her 35-year-old brother showed a similar phenotype with a rather uniform sclerosis of the skull, a thickened  
42 calvarium and an enlarged mandible, which can be noticed from the radiographs (Figure 1D-E). This patient also  
43 was of tall stature (190cm), had a large head (head circumference: 66cm) and a highly increased BMD (T-score:  
44 spine +9.8, femoral neck +7.3). Similar to his sister, he had no syndactyly or other hand malformations.  
45 Information on the presence of additional clinical symptoms was lacking. Other family members were  
46 phenotypically normal.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1.** A. Lateral view of the female patient's face showing a marked mandibular prognathism. B. Plain radiograph of the skull (lateral view) showing uniform sclerosis of the calvaria, skull base and facial bones (particularly the mandible). C. Axial CT-scan of the brain showing marked thickening of the cranial vault. D. Lateral view of the face of the female's brother, who also shows a marked mandibular prognathism. E. Plain radiograph of the skull (lateral view) of the brother, showing uniform sclerosis of the skull and the mandible.

### Mutation analysis

Because mutations in *LRP5* and *SOST* are known to be causal for craniotubular hyperostoses, we evidently included both genes in the mutation screening of the patient. Direct sequencing of the *LRP5* gene revealed no mutations in the coding region of the gene or in the exon-intron boundaries. Instead, we found a homozygous c.499T>C (p.Cys167Arg) mutation in exon 2 of the *SOST* gene (nucleotide numbering refers to the cDNA RefSeq using the A of the ATG translation initiation codon as nucleotide +1) (data not shown).

To investigate whether the mutation segregated with the disease, additional family members were recruited and sequenced. This resulted in the identification of the same homozygous missense mutation in an affected brother. Both unaffected parents and an unaffected sibling were found to be heterozygous carriers. Eighty unrelated healthy control individuals (160 chromosomes) from Turkish origin were checked for the presence of this mutation and all turned out to be negative.



## 8 Piters et al.

**Decreased intracellular and extracellular levels of MT sclerostin**

Since sclerostin is a secreted protein, we initially tested the intra- and extracellular presence of the mutated protein by transient transfection of HEK293T cells with WT and MT mouse Sost-HA plasmids. Transfection with a negative control plasmid (empty pcDNA3.1) was also included. All transfection efficiencies were similar as measured by  $\beta$ -galactosidase activity (data not shown). By immunoblotting, both WT and MT sclerostin were detected in the cell lysates, indicating that the MT protein was formed and recognized by the HA antibody. Moreover, the increased presence of MT sclerostin in the cell lysate suggested an upregulation of expression of the functionally inactive MT sclerostin. In CM, only WT sclerostin was present (Supp. Figure S1A).


To further investigate the effect of the mutation on intra- and extracellular levels of sclerostin, a quantitative electrochemiluminescence assay was used to measure the concentration of WT and MT mouse sclerostin in HEK293T cells (Supp. Figure S1B-C) and Saos-2 cells (data not shown). In addition, human SOST plasmids with or without the mutation were tested in both cell lines. After correction for SOST mRNA, both the intra- and extracellular levels of mouse and human MT sclerostin were lower than those of WT sclerostin. The levels of human sclerostin were consistently higher than those of mouse sclerostin, which may be due to differences in expression efficiency of the plasmids and/or the sensitivity of the assay to mouse and human sclerostin.

**Retention of MT sclerostin in the ER**

As no previous intracellular localization studies had been reported for sclerostin, we hypothesized that, similar to other newly synthesized secreted proteins, it should be produced in the ER from where it is further targeted into the secretory pathway via the Golgi apparatus and cytoplasmic secretory granules. Mutations in proteins often lead to misfolding and subsequent retention in the ER (Ellgaard and Helenius, 2003). To study the effect of the mutation on the subcellular localization of sclerostin in HEK293T and Saos-2 cells, we generated RFP fusion proteins for both WT and MT sclerostin, and the ER was visualized using a green fluorescent ER tracker. By confocal live-cell imaging, we found that the presence of WT sclerostin was concentrated in granular cytoplasmic structures, indicative of secretory granules (Figure 2A-B). The granular staining was most prominent in areas close to the cell membrane and hardly co-localized with the green fluorescent ER tracker, for which the staining was seen as a rather uniform network around the nucleus. The staining pattern of the MT sclerostin-RFP fusion protein was more diffuse and appeared to predominantly co-localize with the ER tracker (Figure 2C-D).


**Decreased antagonistic activity of MT sclerostin**

The effect of the mutation on the antagonistic capacity of sclerostin on Wnt signaling was tested in Saos-2 cells. Cells were transfected with a Wnt reporter construct and stimulated with either a Wnt1 expression plasmid or rec Wnt3a. Transfection of Wnt1 alone resulted in a 2-fold enhancement of Wnt signaling (Figure 3A). However, when the Wnt1 plasmid was co-transfected with an LRP5 expression plasmid, a 13-fold increase in Wnt signaling was observed. Wild type mSost plasmid significantly inhibited Wnt1-stimulated Wnt signaling to almost 50% of its original level ( $p=0,007$ ), whereas the MT mSost plasmid could only induce a non-significant 20% reduction. Stimulation with rec Wnt3a resulted in an almost 20-fold increase in Wnt signaling (Figure 3B). Both mouse and human WT Sost/SOST plasmids significantly inhibited Wnt signaling, and the human SOST plasmid seemed to be more potent. Both MT Sost/SOST plasmids did not inhibit rec Wnt3a-induced signaling.



**Figure 2.** Retention of MT sclerostin in the ER. **A-B.** HEK293T (**A**) and Saos-2 cells (**B**) were transiently transfected with WT *SOST*-RFP plasmid to study the subcellular localization of WT mouse sclerostin (*red* channel). ER staining was performed using a green fluorescent ER tracker (*green* channel). Living cells were viewed using an UltraVIEW dual spinning disk confocal system. Arrows indicate the presence of WT sclerostin in variably sized granular cytoplasmic structures, preferentially in areas close to the cell membrane. The ER networks typically showed the highest density around the nucleus. Merging of the red and green channels clearly revealed that both labels are not co-localized. The latter was most obvious in the many cytoplasmic processes of Saos-2 cells. **C-D.** Similar to Figure 4 A-B, but now HEK293T (**C**) and Saos-2 cells (**D**) were transfected with MT *SOST*-RFP. The orange/yellow color in the merged channel images revealed a major co-localization of MT *SOST* protein with the ER tracker in both cell types. Scale bars are indicated.

10 Piters et al.



**Figure 3.** Decreased level of Wnt signal transduction both in the presence of human and mouse MT sclerostin. **A.** Saos-2 cells were transiently transfected with pGL3-OT, pRL-TK, *Mesdc2*, untagged full length WT-*LRP5* in the presence or absence of *Wnt1-V5*. The antagonistic activity on Wnt signaling was evaluated by co-transfecting either WT or MT *mSOST*. Data were generated in three independent experiments, each performed in triplicate. Bars represent mean values  $\pm$  SD. \*  $p < 0.05$  cells transfected with WT *mSOST* compared to cells transfected without WT *mSOST*. **B.** Saos-2 cells were transfected with untagged full length WT-*LRP5* and BAT-luc with or without mouse and human WT or MT *SOST* expression vectors and stimulated with rec Wnt3a 24h after transfection (n=8). Bars represent mean values  $\pm$  SD. \*  $p < 0.05$  cells transfected with mouse or human WT *SOST* compared to cells transfected without mouse or human WT *SOST*. All data were corrected for differences in transfection efficiency by co-transfection with constitutively active *Renilla*-luciferase expression plasmids.

### Impaired binding of MT sclerostin to LRP5

Co-IP experiments were performed to evaluate the effect of the mutation on the ability of sclerostin to interact with LRP5. HEK293 cells were transfected with constructs either expressing truncated LRP5-myc (encoding only the extracellular part of the protein), WT-sclerostin-HA, or MT-sclerostin-HA. Figure 4A illustrates that truncated LRP5-myc and WT-sclerostin-HA were expressed in the CM, while MT-sclerostin-HA was found exclusively in the cell lysate (Figure 4A). Subsequently, CM of the truncated LRP5-myc transfected cells was mixed with either CM of WT-sclerostin-HA transfected cells or cell lysates of MT-sclerostin-HA transfected cells to determine binding between the extracellular part of LRP5 and WT- or MT-sclerostin. From the immune complexes, HA-tagged WT- and MT-sclerostin were precipitated using EZ-view™ Red Anti-HA affinity gel and immunoblotted with c-myc antibodies to demonstrate co-IP of truncated LRP5-myc with WT- or MT-sclerostin-HA. Truncated LRP5-myc was detected in precipitates that contained WT-sclerostin-HA, but not in precipitates that contained MT-sclerostin-HA, suggesting that the mutation in sclerostin resulted in a reduced affinity for LRP5 (Figure 4B). The immune complexes were also immunoblotted with anti-HA to demonstrate the presence of either WT- or MT-sclerostin-HA in all samples (Figure 4B).


### DISCUSSION

The clinical and radiological features of patients with SCL are thought to be due to complete absence of sclerostin resulting from loss-of-function mutations in the *SOST* gene. These include both nonsense mutations and splice site mutations (Balemans, et al., 2005a; Balemans, et al., 2001; Brunkow, et al., 2001). In this study, we found for the first time a missense mutation in the *SOST* gene causing a cysteine to arginine amino acid substitution at position 167. The pathogenicity of this genetic variant was demonstrated by the cosegregation of the mutation with the disease in the, albeit small, Turkish family and the absence of the variant in 160 chromosomes of 80 control subjects of a matched ethnic background.

The nature of the mutation is strongly indicative for a pathogenic mutation, since the amino acid substitution results in the loss of a cysteine residue. Alignment of homologous cDNA and protein sequences using CLUSTALW (<http://www.ebi.ac.uk/Tools/clustalw2/index.html>) showed that the affected cysteine is highly conserved in multiple species (data not shown). Moreover, this cysteine is the last of six cysteines forming the characteristic cystine-knot motif (residues 80-167) (Avsian-Kretschmer and Hsueh, 2004). Furthermore, the cysteine to arginine substitution implies a change from an uncharged polar amino acid into a basic amino acid. We tested the putative consequences of this substitution in several software programs, such as Polyphen and SIFT (Ng and Henikoff, 2003; Ramensky, et al., 2002). These programs sort intolerant from tolerant amino acid substitutions, principally on the basis of sequence-homology. Polyphen also includes a search for structural parameters to predict whether an amino acid substitution in a protein has a possible phenotypic effect. According to both programs, the mutation is damaging with a high probability.

Cysteine residues are characterized by thiol-groups that can form disulfide bonds, covalent crosslinks between cysteine side chains that play an important role in the rate and efficiency of protein folding and most importantly in the stability of folded proteins. Some disulfide bonds have been shown to be indispensable for efficient secretion by promoting the production of more compact folded intermediates (Wittrup, 1995). Removal of disulfides by site-directed mutagenesis has been demonstrated to be sufficient to cause misfolding, aggregation and impaired secretion of several proteins (Bedows, et al., 1994; Chen, et al., 1992; Omura, et al., 1992; Segal, et al., 1992; Shani and Pines, 1992; Sukanuma, et al., 1989; Taniyama, et al., 1988).

12 Piters et al.



36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

**Figure 4.** Impaired binding of MT sclerostin to LRP5. **A.** Total cell lysates and CM from HEK293T cells transfected with WT or MT *SOST* were analyzed for the expression of HA-tagged sclerostin by immunoblotting using HA antibodies. Expression of LRP5-myc protein in CM was evaluated by immunoblotting with *c-myc* antibodies. A negative control (empty pcDNA3.1) was included in both immunoblotting experiments. Equal protein loading was confirmed by immunoblotting of total cell lysates for  $\beta$ -actin. **B.** Mixtures of CM containing truncated WT-LRP5-myc and either CM containing WT-sclerostin-HA (lane 4) or cell lysates containing MT-sclerostin-HA (lane 5) were immunoprecipitated using EZ-view™ Red Anti-HA affinity gels. Cells that were transfected only with LRP5-myc (lane 1) or WT and MT *SOST*-HA expression vectors (lane 2-3) were used as controls. Immunodetection of HA-immunoprecipitated protein was performed with both anti-HA and anti-myc. From lane 4 and 5 it is clear that WT but not MT sclerostin-HA was able to precipitate LRP5-myc.

51  
52  
53  
54  
55  
56  
57  
58  
59  
60

With regard to the p.Cys167Arg mutation in the *SOST* gene, we used NMR structure analysis of mouse sclerostin to predict the possible influence on the sclerostin fold. Due to the architecture of the cystine-knot motif three peptide loops emanate from the cystine-knot, two of which run in the same direction (and form the so-called Finger 1 and 2), whereas the third emanates into the opposite direction. Finger 1 and 2 of the WT sclerostin are well defined forming two two-stranded anti-parallel  $\beta$ -sheets, whereas the third loop is highly flexible and disordered (Supp. Figure S2A) (Veverka, et al., 2009; Weidauer, et al., 2009). A zoom into the cystine-knot motif showed that it is rather loosely packed, with amino acid residues between the cysteine residues pointing towards

1  
2  
3 the solvent, indicating that the cystine-knot of sclerostin exhibits partly elevated flexibility (Supp. Figure S2B).  
4 Simulations *in silico* suggested that mutating cysteine 167 (equivalent to cysteine 142 of the mature protein) to  
5 arginine not only disrupts the outer disulfide bond present in the cystine-knot motif (Supp. Figure S2C) but also  
6 requires conformational changes of the lower loop segment due to the increased spatial requirements of the larger  
7 arginine side chain. This will lead to global misfolding due to a decreased stability of the cystine-knot motif and  
8 the presence of an accessible reactive thiol-group at the protein surface as one cysteine residue remains unpaired.  
9 Even if a global misfolding does not occur, the large space requirements of the arginine side chain will lead to a  
10 further disorder of the loop segment, which has been proposed to be important for the activity of sclerostin by  
11 mapping the binding site of a neutralizing antibody to the tip of the loop segment (Veverka, et al., 2009).  
12 Molecular dynamics simulation indeed showed a local unfolding of the remaining cysteine network, as the side  
13 chain of arginine introduced at position 167 (for mature sclerostin residue numbering is not accounting for the 25  
14 residue signal peptide: Cys167 corresponds to Cys142) points towards the interior of the former cystine-knot  
15 requiring an opening of the ring in order to avoid steric clashes between the bulky side chain of the introduced  
16 arginine and surrounding residues like Cys109, Gly107 and Ser106. This rearrangement is complemented by  
17 conformational changes in the amino terminus, as the former packing has to be relieved to create enough space for  
18 Arg167. In addition, loss of the disulfide bond between Cys109 and Cys167 (now Arg167) enhances  
19 conformational variability in the loop segment since the few hydrophobic interactions between the antiparallel  
20 peptide segments of the loop are further weakened.  
21

22 This *in silico* modeling suggests that loss of this crucial cysteine may indeed result in impaired folding and  
23 hence be responsible for retention of the mutant protein in the ER. This is normally followed by degradation  
24 through delivery to the 26S proteasome in the cytoplasm or by lysosomal degradation by autophagy. The latter  
25 mechanism is especially used for misfolded proteins that aggregate in the secretory pathway or in the cytosol  
26 (Klionsky, 2007; Nakatsukasa and Brodsky, 2008). Using subcellular localization experiments, we were able to  
27 show that MT sclerostin indeed does not exit the ER, explaining the decreased extracellular levels of MT sclerostin  
28 compared to WT found by immunoblotting and electrochemiluminescence. In addition, in reporter assays MT  
29 sclerostin was found to have strongly decreased antagonistic activity on Wnt signaling. Using co-IP experiments,  
30 we demonstrated that also the binding affinity of MT sclerostin for LRP5, which is required for its antagonist  
31 activity, is decreased. *In vivo*, these effects resulted in a complete loss of function of sclerostin reflected by a  
32 phenotype that is highly similar to that of previously reported patients with SCL. In the same way, loss-of-function  
33 mutations derived from folding problems in a variety of proteins with different activities, lead to retention of  
34 mutated proteins in the ER and their consequent degradation. This mechanism lies at the basis of a large number of  
35 ER-derived diseases, reviewed by Aridor *et al* (Aridor, 2007). In addition to this loss-of-function, increased levels  
36 of ER stress, known as unfolded protein response (UPR) (i.e. induction of inflammatory responses or cellular  
37 apoptosis), due to inability of the ER to efficiently dispose of the mutant protein, can contribute substantially to  
38 disease pathogenesis (Aridor, 2007; Boot-Handford and Briggs). It has been reported that strongly secretory cells  
39 (and maybe also the osteocyte) are extremely susceptible to this UPR, which often results in a pathogenic outcome  
40 (Boot-Handford and Briggs). Since we did not perform experiments to further investigate this disease mechanism,  
41 our data can not exclude the possibility that this mechanism additionally contributes to the phenotype in this  
42 family.  
43

44 In conclusion, the present work describes here the first missense mutation in the *SOST* gene encoding sclerostin  
45 in a patient with SCL. This missense mutation involves one of the cysteine residues of the cystine-knot motif of  
46 sclerostin. The mutation has a devastating effect on the biological function of sclerostin by reducing extracellular  
47 sclerostin levels as well as the binding capacity of sclerostin to LRP5 and, thereby, its antagonistic activity on  
48 canonical Wnt signaling. It is possible that ER stress and UPR, as a consequence of the inability of the ER to  
49 efficiently dispose of the mutant protein, also contribute to the disease phenotype.  
50

#### 51 ACKNOWLEDGMENTS

52  
53 This work was supported by the European Commission [HEALTH-F2-2008-201099, TALOS]; and by grants  
54 from the 'Fonds voor Wetenschappelijk Onderzoek' [FWO, G.0117.06], from the Special Research Funds (BOF  
55 TOP and NOI) of the University of Antwerp, all to W.V.H.. Additional support was provided by Senternovem/IOP  
56 Genomics (IGE07001A).  
57  
58  
59  
60

14 Piters et al.

## REFERENCES


- A Freire de Paes Alves JR, L Cardoso, MM Rabelo. 1982. Sclerosteosis: a marker for Dutch ancestry? *Rev Brasil Genet* 4:825-834.
- Aridor M. 2007. Visiting the ER: the endoplasmic reticulum as a target for therapeutics in traffic related diseases. *Adv Drug Deliv Rev* 59(8):759-81.
- Avsian-Kretchmer O, Hsueh AJ. 2004. Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. *Mol Endocrinol* 18(1):1-12.
- Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W. 2005a. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. *Bone* 36(6):943-7.
- Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foerzler D, Van Hul W. 2001. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). *Hum Mol Genet* 10(5):537-43.
- Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foerzler D, Van Hul W. 2002. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. *J Med Genet* 39(2):91-7.
- Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, Van Hul W. 2008. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. *Calcif Tissue Int* 82(6):445-53.
- Balemans W, Van Den Ende J, Freire Paes-Alves A, Dikkers FG, Willems PJ, Vanhoenacker F, de Almeida-Melo N, Alves CF, Stratakis CA, Hill SC, Van Hul W. 1999. Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. *Am J Hum Genet* 64(6):1661-9.
- Balemans W, Van Wesenbeeck L, Van Hul W. 2005b. A clinical and molecular overview of the human osteopetroses. *Calcif Tissue Int* 77(5):263-74.
- Bedows E, Norton SE, Huth JR, Sukanuma N, Boime I, Ruddon RW. 1994. Misfolded human chorionic gonadotropin beta subunits are secreted from transfected Chinese hamster ovary cells. *J Biol Chem* 269(14):10574-80.
- Beighton P, Barnard A, Hamersma H, van der Wouden A. 1984. The syndromic status of sclerosteosis and van Buchem disease. *Clin Genet* 25(2):175-81.
- Beighton P, Davidson J, Durr L, Hamersma H. 1977. Sclerosteosis - an autosomal recessive disorder. *Clin Genet* 11(1):1-7.
- Beighton P, Durr L, Hamersma H. 1976. The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. *Ann Intern Med* 84(4):393-7.
- Boot-Handford RP, Briggs MD. The unfolded protein response and its relevance to connective tissue diseases. *Cell Tissue Res* 339(1):197-211.
- Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. *N Engl J Med* 346(20):1513-21.
- Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J. 2001. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. *Am J Hum Genet* 68(3):577-89.
- Bueno M, Oliván G, Jimenez A, Garagorri JM, Sarria A, Bueno AL, Bueno M, Jr., Ramos FJ. 1994. Sclerosteosis in a Spanish male: first report in a person of Mediterranean origin. *J Med Genet* 31(12):976-7.
- CH Kelley JL. 1946. Albers-Schonberg disease: a family survey. *Radiology* 47:507-513.
- Chen XZ, Shafer AW, Yun JS, Li YS, Wagner TE, Kopchick JJ. 1992. Conversion of bovine growth hormone cysteine residues to serine affects secretion by cultured cells and growth rates in transgenic mice. *Mol Endocrinol* 6(4):598-606.
- Dixon JM, Cull RE, Gamble P. 1982. Two cases of Van Buchem's disease. *J Neurol Neurosurg Psychiatry* 45(10):913-8.

- 1  
2  
3 Ellgaard L, Helenius A. 2003. Quality control in the endoplasmic reticulum. *Nat Rev Mol Cell Biol* 4(3):181-91.
- 4  
5 Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R. 2006. Bone density ligand, Sclerostin, directly  
6 interacts with LRP5 but not LRP5G171V to modulate Wnt activity. *J Bone Miner Res* 21(11):1738-49.
- 7  
8 Gueguen R, Jouanny P, Guillemin F, Kuntz C, Pourel J, Siest G. 1995. Segregation analysis and variance components analysis  
9 of bone mineral density in healthy families. *J Bone Miner Res* 10(12):2017-22.
- 10  
11 Hamersma H, Gardner J, Beighton P. 2003. The natural history of sclerosteosis. *Clin Genet* 63(3):192-7.
- 12  
13 Hill SC, Stein SA, Dwyer A, Altman J, Dorwart R, Doppman J. 1986. Cranial CT findings in sclerosteosis. *AJNR Am J  
Neuroradiol* 7(3):505-11.
- 14  
15 Johnson ML, Harnish K, Nusse R, Van Hul W. 2004. LRP5 and Wnt signaling: a union made for bone. *J Bone Miner Res*  
16 19(11):1749-57.
- 17  
18 Klionsky DJ. 2007. Autophagy: from phenomenology to molecular understanding in less than a decade. *Nat Rev Mol Cell Biol*  
19 8(11):931-7.
- 20  
21 Krall EA, Dawson-Hughes B. 1993. Heritable and life-style determinants of bone mineral density. *J Bone Miner Res* 8(1):1-9.
- 22  
23 Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M,  
24 Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. 2008.  
25 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. *J Bone Miner Res*  
26 23(6):860-9.
- 27  
28 Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. 2005. Sclerostin binds to LRP5/6 and antagonizes canonical  
29 Wnt signaling. *J Biol Chem* 280(20):19883-7.
- 30  
31 Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM,  
32 Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A,  
33 Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT,  
34 Recker SM, Van Eerdewegh P, Recker RR, Johnson ML. 2002. A mutation in the LDL receptor-related protein 5 gene  
35 results in the autosomal dominant high-bone-mass trait. *Am J Hum Genet* 70(1):11-9.
- 36  
37 Nakatsukasa K, Brodsky JL. 2008. The recognition and retrotranslocation of misfolded proteins from the endoplasmic  
38 reticulum. *Traffic* 9(6):861-70.
- 39  
40 Ng PC, Henikoff S. 2003. SIFT: Predicting amino acid changes that affect protein function. *Nucleic Acids Res* 31(13):3812-4.
- 41  
42 NL Higinbotham SA. 1941. Osteopetrosis: four cases in one family. *Am J Surgery* 53:444-454.
- 43  
44 Omura F, Otsu M, Kikuchi M. 1992. Accelerated secretion of human lysozyme with a disulfide bond mutation. *Eur J Biochem*  
45 205(2):551-9.
- 46  
47 Pietruschka G. 1958. [Further information on marble bones (Albers-Schonberg disease) with remarks on differential  
48 diagnosis.]. *Klin Monatsblätter Augenheilkd Augenarztl Fortbild* 132(4):509-25.
- 49  
50 Piters E, Boudin E, Van Hul W. 2008. Wnt signaling: a win for bone. *Arch Biochem Biophys* 473(2):112-6.
- 51  
52 Ramensky V, Bork P, Sunyaev S. 2002. Human non-synonymous SNPs: server and survey. *Nucleic Acids Res* 30(17):3894-  
53 900.
- 54  
55 Segal MS, Bye JM, Sambrook JF, Gething MJ. 1992. Disulfide bond formation during the folding of influenza virus  
56 hemagglutinin. *J Cell Biol* 118(2):227-44.
- 57  
58 Semenov M, Tamai K, He X. 2005. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. *J Biol Chem*  
59 280(29):26770-5.
- 60  
61 Semenov MV, He X. 2006. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by  
62 SOST. *J Biol Chem* 281(50):38276-84.
- 63  
64 Shani O, Pines O. 1992. The relationship between disulphide bond formation, processing and secretion of lipo-beta-lactamase  
65 in yeast. *Mol Microbiol* 6(2):189-95.




## 16 Pitters et al.

- 1  
2  
3 Staehling-Hampton K, Proll S, Paepfer BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P,  
4 Papapoulos S, Hamersma H, Brunkow ME. 2002. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is  
5 associated with van Buchem disease in the Dutch population. *Am J Med Genet* 110(2):144-52.  
6  
7 Stein SA, Witkop C, Hill S, Fallon MD, Viernstein L, Gucer G, McKeever P, Long D, Altman J, Miller NR, Teitelbaum SL,  
8 Schlesinger S. 1983. Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. *Neurology*  
9 33(3):267-77.  
10 Suganuma N, Matzuk MM, Boime I. 1989. Elimination of disulfide bonds affects assembly and secretion of the human  
11 chorionic gonadotropin beta subunit. *J Biol Chem* 264(32):19302-7.  
12  
13 Sugiura Y, Yasuhara T. 1975. Sclerosteosis. A case report. *J Bone Joint Surg Am* 57(2):273-7.  
14  
15 Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA. 2004. Sclerostin promotes the apoptosis  
16 of human osteoblastic cells: a novel regulation of bone formation. *Bone* 35(4):828-35.  
17  
18 Tacconi P, Ferrigno P, Cocco L, Cannas A, Tamburini G, Bergonzi P, Giagheddu M. 1998. Sclerosteosis: report of a case in a  
19 black African man. *Clin Genet* 53(6):497-501.  
20  
21 Taniyama Y, Yamamoto Y, Nakao M, Kikuchi M, Ikehara M. 1988. Role of disulfide bonds in folding and secretion of human  
22 lysozyme in *Saccharomyces cerevisiae*. *Biochem Biophys Res Commun* 152(3):962-7.  
23  
24 van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals L, Balemans W, Oostenbroek HJ, Van Hul  
25 W, Hamersma H, Dikkers FG, Hamdy NA, Papapoulos SE, Lowik CW. 2009. Sclerostin in mineralized matrices and van  
26 Buchem disease. *J Dent Res* 88(6):569-74.  
27  
28 van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke  
29 P, Lowik CW. 2004. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP  
30 antagonist. *J Exp Med* 199(6):805-14.  
31  
32 van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten  
33 Dijke P, Lowik CW. 2007. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated  
34 bone formation. *J Bone Miner Res* 22(1):19-28.  
35  
36 van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW. 2005. SOST/sclerostin, an osteocyte-derived negative regulator of  
37 bone formation. *Cytokine Growth Factor Rev* 16(3):319-27.  
38  
39 Van Hul W, Balemans W, Van Hul E, Dikkers FG, Obee H, Stokroos RJ, Hilderling P, Vanhoenacker F, Van Camp G, Willems  
40 PJ. 1998. Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. *Am J Hum Genet*  
41 62(2):391-9.  
42  
43 Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman  
44 ML, De Vernejoul MC, Bollerslev J, Van Hul W. 2003. Six novel missense mutations in the LDL receptor-related protein 5  
45 (LRP5) gene in different conditions with an increased bone density. *Am J Hum Genet* 72(3):763-71.  
46  
47 Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L,  
48 Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD. 2009. Characterization of the structural features and  
49 interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. *J Biol Chem*  
50 284(16):10890-900.  
51  
52 Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H, Mueller TD. 2009. NMR structure of the Wnt modulator  
53 protein Sclerostin. *Biochem Biophys Res Commun* 380(1):160-5.  
54  
55 Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-  
56 Hampton K, Appleby M, Brunkow ME, Latham JA. 2003. Osteocyte control of bone formation via sclerostin, a novel BMP  
57 antagonist. *Embo J* 22(23):6267-76.  
58  
59 Wittrup KD. 1995. Disulfide bond formation and eukaryotic secretory productivity. *Curr Opin Biotechnol* 6(2):203-8.  
60



**Supp. Figure S1.** Decreased intra- and extracellular levels of MT sclerostin. **A.** Total cell lysates and CM from HEK293T cells transfected with WT or MT *SOST* or empty vector were analyzed for the expression of HA-tagged sclerostin by immunoblotting using an HA antibody. Equal protein loading was confirmed by immunoblotting of total cell lysates for  $\beta$ -actin. One representative experiment of three independent immunoblotting experiments is depicted. **B.** Quantitative expression analysis of sclerostin in cell lysates of HEK293T cells transfected with WT and MT constructs of both mouse and human *SOST* or an empty control vector using the MULTI-ARRAY<sup>®</sup> Human sclerostin assay (MSD). Sclerostin levels were corrected for *SOST* mRNA expression levels for each of the plasmids determined by RT-PCR analysis. **C.** Same in CM of transfected HEK293T cells.



**Supp. Figure S2.** Effect of the mutating cysteine 167 to arginine on the NMR structure of sclerostin. **A.** Ribbon representation of the NMR structure ensemble of mouse sclerostin (residues Lys73 to Arg169 is shown, residue numbering includes the 25 residue signal peptide, PDB entry 2KD3). The secondary structure elements are indicated in yellow ( $\beta$ -strand), red ( $\alpha$ -helix) and green (coil). The overlay of the 15 NMR structures of the ensemble shows that finger 1 and 2 are well defined, whereas the loop is highly flexible and disordered. **B.** Detail of the cystine-knot of sclerostin. The cystine-knot is rather loosely packed, with amino acid residues between the cysteine residues pointing towards the solvent, indicating that the cystine-knot of sclerostin is flexible in part. The cysteine residue, which is mutated in the patient, is colored in magenta, numbering is according to full-length sclerostin protein starting with residue 1. **C.** Same region displayed for MT mouse sclerostin variant. Mutating cysteine 167 to arginine disrupts the outer disulfide bond present in the cystine-knot motif.